Literature DB >> 2981780

A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Q Y Yao, A B Rickinson, M A Epstein.   

Abstract

A panel of 24 healthy seropositive donors have been followed prospectively over a period of 15 months and monitored (1) for the level of EB virus shedding in the throat by means of a sensitive cord-blood transformation assay; (2) for the level of virus-infected B cells in the blood via a new in vitro protocol where "spontaneous transformation" can be seen to titrate against input cell number; (3) for anti-EB viral antibody titres and (4) for the prevailing level of virus-specific memory T cells in the circulation. Six donors shed easily detectable levels of EB virus into throat washings on every occasion of testing, whilst 16 other donors shed lower levels of virus detectable in throat washings on a majority (10 donors) or on a minority (6 donors) of test occasions; only 2/24 donors gave no evidence of virus shedding at any time. There was a direct relationship between the EB virus shedder status of an individual (i.e., the level of virus replication in the pharynx) and the number of infected B cells present in the circulation. These results indicate that chronic, usually low-grade, replication of the virus at some permissive site in the oro- and/or naso-pharynx is very often a stable accompaniment of the asymptomatic EB virus carrier state, and may indeed be essential for the long-term maintenance of that state.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981780     DOI: 10.1002/ijc.2910350107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  70 in total

1.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Authors:  G M Gillespie; M R Wills; V Appay; C O'Callaghan; M Murphy; N Smith; P Sissons; S Rowland-Jones; J I Bell; P A Moss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

4.  Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Authors:  D M Walling; S N Edmiston; J W Sixbey; M Abdel-Hamid; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

5.  Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction.

Authors:  H J Wagner; G Bein; A Bitsch; H Kirchner
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

6.  Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals.

Authors:  Giao T Huynh; Libin Rong
Journal:  J Theor Biol       Date:  2012-06-07       Impact factor: 2.691

Review 7.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

8.  Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo.

Authors:  Lauri L Laichalk; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 9.  Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.

Authors:  D J Moss; I S Misko; T B Sculley; A Apolloni; R Khanna; S R Burrows
Journal:  Springer Semin Immunopathol       Date:  1991

Review 10.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.